Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company focused on the development of therapies that inhibit the complement and leukotriene systems, which are components of the innate immune response. The company operates within the biopharmaceuticals and rare disease therapeutics industries, with an emphasis on inflammatory and autoimmune conditions that have high unmet medical needs.
Akari’s primary asset has been nomacopan (Coversin), a recombinant protein designed to inhibit both complement component C5 and leukotriene B4. The company has historically targeted rare and orphan indications, including bullous pemphigoid and hematopoietic stem cell transplant–associated thrombotic microangiopathy (HSCT-TMA). Akari was founded in the United Kingdom and became publicly traded through a NASDAQ listing, evolving from an early-stage research organization into a clinical development company through in-licensing and internal development of immune-modulating technologies.
Business Operations
Akari’s operations have been centered on drug development and clinical research, with no commercialized products generating material revenue. The company’s activities primarily involve preclinical research, clinical trials, regulatory engagement, and intellectual property management related to complement inhibition technologies.
Operations have historically been split between United States and United Kingdom–based functions, including executive management, clinical operations, and regulatory oversight. Akari does not maintain large-scale manufacturing facilities and has relied on third-party contract research organizations and manufacturing partners to support clinical development. Data inconclusive based on available public sources regarding the current status of active clinical programs and operational scale following recent restructuring activities.
Strategic Position & Investments
Akari’s strategic direction has focused on leveraging complement pathway inhibition to address rare, severe inflammatory diseases where targeted immune modulation may provide advantages over broader immunosuppressive therapies. The dual-action mechanism of nomacopan has been positioned as a potential differentiator relative to single-target complement inhibitors.
Historically, the company has invested primarily in advancing nomacopan through clinical development rather than building a diversified pipeline or acquiring multiple assets. Public disclosures indicate limited acquisition activity, and no material portfolio of operating subsidiaries has been reported. Recent filings and market disclosures suggest the company has evaluated strategic alternatives, including asset monetization and restructuring, though the long-term strategic outcome remains unclear based on publicly available information.
Geographic Footprint
Akari Therapeutics is headquartered in the United Kingdom and maintains a significant corporate and regulatory presence in the United States, reflecting its NASDAQ listing and focus on U.S.-based clinical development and capital markets.
The company’s clinical and regulatory activities have primarily targeted North America and Europe, with clinical trial sites and regulatory interactions spanning these regions. Akari does not report a broad commercial footprint, and its international presence has been driven by development needs rather than product sales or large-scale operations.
Leadership & Governance
Akari is governed by a board of directors and executive leadership team with experience in biotechnology, drug development, and capital markets. Leadership has emphasized capital discipline, portfolio prioritization, and strategic evaluation of development assets in response to financial and market conditions.
Key executives reported in public filings and company disclosures include:
- Clive Richardson – Chief Executive Officer
- Mark Chappell – Chief Financial Officer
- Graham Fraser – Non-Executive Chairman
Data inconclusive based on available public sources regarding recent changes in executive roles and governance structure following corporate restructuring activities.